GW-501516, commonly sold under the name Cardarine, is an experimental drug that was originally developed in the 1990s by GlaxoSmithKline and Ligand Pharmaceuticals to treat metabolic and cardiovascular diseases. It is not a steroid, not a SARM (selective androgen receptor modulator), and was never approved for human use. The pharmaceutical company abandoned the compound after preclinical animal studies revealed serious safety concerns, including cancer development in rodents. Despite this, GW-501516 has gained a following in bodybuilding and endurance sports circles, where it’s sold through black market websites and gray-market supplement shops.
How GW-501516 Works in the Body
GW-501516 activates a specific protein inside cells called PPARδ, a receptor that regulates how the body processes fat and sugar for energy. When this receptor is switched on, it shifts muscle cells to burn fatty acids instead of carbohydrates as their primary fuel source. Think of it like flipping a metabolic switch: rather than relying on stored sugar (glycogen), muscles start pulling more energy from fat. This mechanism is why GW-501516 was initially explored as a potential treatment for obesity, type 2 diabetes, and metabolic syndrome.
In animal studies, activating this receptor also suppressed glucose production in the liver, improved insulin sensitivity, and reduced the release of free fatty acids from fat cells. These effects, combined with the shift toward fat burning in muscles, made the compound look promising on paper for people with metabolic disorders.
Why It’s Not a SARM
GW-501516 is frequently grouped with SARMs on supplement websites and in online fitness communities, but the two work through completely different mechanisms. SARMs bind to androgen receptors, the same receptors that testosterone targets, to promote muscle growth with fewer side effects than traditional anabolic steroids. GW-501516 does not interact with androgen receptors at all. It targets PPARδ, a metabolic regulator that has nothing to do with testosterone or muscle-building hormones.
The World Anti-Doping Agency (WADA) classifies them separately. SARMs fall under “other anabolic agents,” while GW-501516 is listed under “metabolic modulators.” Both categories are banned at all times, in and out of competition. The misclassification persists largely because the same online retailers sell both types of compounds side by side, and the fitness community has lumped them together out of convenience.
Effects Observed in Human Trials
Before development was halted, GW-501516 did undergo limited human clinical testing. In a 12-week trial involving 268 patients with low HDL (“good”) cholesterol, participants received daily doses of 2.5, 5, or 10 mg. The results were notable for lipid profiles. At the 10 mg dose, HDL cholesterol rose by 16.9%, while LDL (“bad”) cholesterol dropped by 7.3%. Triglycerides fell by 16.9%, and free fatty acids in the blood declined by roughly 19% across all dose groups, compared to a 13.7% increase in the placebo group.
A smaller exploratory study of 37 subjects showed even more dramatic shifts in cholesterol subtypes. Very low-density lipoprotein particles dropped by 19%, intermediate-density lipoprotein fell by 52%, and LDL decreased by 14%, with most of that reduction coming from the small, dense LDL particles considered most harmful for heart health. The number of HDL particles increased by 10%, predominantly the medium and large particles associated with cardiovascular protection.
Blood sugar levels stayed stable across all dose groups. Insulin levels dropped modestly (about 5.8 to 5.9%) at the lower and intermediate doses, suggesting improved insulin sensitivity. Interestingly, this insulin-lowering effect disappeared at the highest dose, for reasons that remain unclear.
Why It Was Abandoned: The Cancer Problem
GlaxoSmithKline terminated GW-501516’s development after preclinical toxicology studies in rodents revealed rapid tumor growth across multiple organs. These were standard safety studies that pharmaceutical companies conduct before a drug can advance toward approval. The results were severe enough that the company walked away from the compound entirely, despite the promising metabolic data.
WADA took the unusual step of issuing a direct public safety alert in 2013 after learning that athletes were buying and using the compound on the black market. The agency stated plainly that “clinical approval has not, and will not be given for this substance” because of the toxicities discovered in animal testing. This kind of warning from WADA is rare and signals a level of concern beyond the typical prohibition of a performance-enhancing substance.
The core debate in online fitness forums centers on whether animal cancer findings translate to humans. It’s a reasonable scientific question in general, but the reality is that no long-term human safety data exists for GW-501516. The compound never made it far enough through the approval process to generate that data, precisely because the animal findings were alarming enough to stop the research.
Current Legal and Regulatory Status
GW-501516 is not approved by the FDA or any other regulatory agency for any use. It is not a dietary supplement. Products containing it are sold illegally through online retailers, often marketed alongside SARMs under labels like “research chemicals” or “not for human consumption” to skirt regulations.
The FDA has taken enforcement action against companies selling these products. In warning letters to retailers, the agency has cited serious safety concerns including liver toxicity, increased risk of heart attack, and increased risk of stroke associated with SARM-type products. These retailers often sell GW-501516 in the same product lines, and the compounds share the same lack of manufacturing oversight, meaning buyers have no guarantee of purity, dose accuracy, or the absence of contaminants.
WADA has banned GW-501516 at all times since adding it to its prohibited list, and anti-doping laboratories have developed tests to detect it. Multiple athletes have tested positive. Anyone competing in a sport governed by WADA or a national anti-doping organization risks a suspension for using it, regardless of whether they knew it was in a product they purchased.
What People Use It For
In the fitness and bodybuilding world, GW-501516 is primarily used for two purposes: fat loss and endurance enhancement. Users report being able to sustain cardio exercise for significantly longer periods, which aligns with the drug’s mechanism of shifting energy metabolism toward fat oxidation. It’s popular during “cutting” phases when athletes try to lose body fat while preserving muscle.
Because it doesn’t act on androgen receptors, GW-501516 does not cause the hormonal side effects associated with steroids or SARMs, such as testosterone suppression or changes in estrogen levels. This is part of its appeal, particularly for users who want to avoid post-cycle therapy. However, the absence of hormonal side effects does not mean the compound is safe. The cancer findings in animal studies represent a fundamentally different category of risk, one that hormonal management protocols cannot address.
Products sold online typically come in liquid or capsule form at doses ranging from 10 to 20 mg per day, with cycles lasting 8 to 12 weeks. None of these protocols are based on clinical guidance, since the drug was never approved. They originate entirely from user experimentation shared on forums and social media.